Venus Concept Inc.

VERO
Country: United StatesPrice: $0.31Market Cap: $220,539.423

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2962 (Top 95.6%)PASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Annual history · FY 2024

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30 · TTM ended 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

TTM ended 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-03-31

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-04-01

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-03-31

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment · TTM ended 2025-09-30 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Qualitative assessment

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-04-01

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-04-01 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-03-31

Score computed: 2026-11-14

TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Price history 2025-01-01–2026-04-01 · Annual history · FY 2024

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-13

Score computed: 2026-11-14

TTM ended 2025-09-30 · Annual history · FY 2024 · Price history 2025-01-01–2026-04-01

Latest source filing: 2025-11-13

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 7✗ 21▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.1x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-133.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-133.7%, ROC=-206.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.1x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-19601.9%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-5073.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.1x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-24786.95%; #6268/6340 (top 98.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+12.1203; #174/6449 (top 2.7%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+266.9636; #55/5247 (top 1.0%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-9408.30%; #4477/4519 (top 99.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-43.2M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-11.2M
      ✗LynchPositive and growing
      Operating Cash Flow$-11.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-16.23%, ROA=-68.93%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-5073.5%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/10 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-9408.3%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/10 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-20.7M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-9408.30%; #4477/4519 (top 99.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -23.9% vs Rev: -15.1%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-15.1%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 66.3% -> 68.3%, operating margin -35.1% -> -41.9%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR-10.1%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio0.90
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-42.7%
      ✗Buffett> 10%
      ROIC - WACC-52.7%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-206.8%
      ✗Greenblatt> 25%
      Current Ratio Change YoY2.13 -> 1.60
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.82x -> 0.95x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities0.90
      ✗Dreman> 1.5
      Return on Invested Capital-83.8%
      ✗Munger> 15%
      ROIC (high and growing)FY2022: ROIC=-32.1%; FY2023: ROIC=-39.4%; FY2024: ROIC=-51.0%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -51.0%)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 5✗ 30▾

      15 of 16 flag VERO's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/11 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/11 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-563.9%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-41.9% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-43.2M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-2045.1%
      ✗Lynch> 15%
      EBIT / Enterprise Value-133.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-133.7%, ROC=-206.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-68.93%
      ✗PiotroskiROA > 0
      ROA Change YoY-39.77% -> -68.93% (delta: -29.15%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-16.23%, ROA=-68.93%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY68.3% -> 68.3%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-92.3%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-2045.1%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.1x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-860.0% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-59.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-2045.1%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-35.1% (2022) -> -41.9% (2024)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 66.3% -> 68.3%, operating margin -35.1% -> -41.9%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-24786.95%; #6268/6340 (top 98.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+61.49%; #449/3702 (top 12.1%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-2045.08%; #5192/5226 (top 99.3%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1794; #4110/5884 (top 69.9%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 14▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2962✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag VERO's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current AssetsLT Debt $5.0M vs NCA $-4.8M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 11.25, IC: -7.5x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity11.25
      ✗Lynch< 0.33
      Cash - Long-term Debt$-0.7M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change75.59% -> 46.11%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.90
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity11.25
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels11.25
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-7.5x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity11.25
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-11.2488; #4158/4210 (top 98.8%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($220,539.423)
    Revenue: $64.8M-15.1% YoY
    Net Income: $47.0M-26.2% YoY

    Financial Snapshot

    Operating Margin-41.9%
    Return on Equity-1983.8%
    Debt / Equity16.76
    Current Ratio1.60
    EPS (Diluted)$-71.21

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2025-09-30

    2024-10-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

    Q3 FY 2025

    2025-07-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q2 FY 2025

    2025-04-01 – 2025-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2025

    2025-01-01 – 2025-03-31

    Sources
    FY 2024
    Sources
    • 10-K · 2025-03-31
    FY 2023
    Sources
    • 10-K · 2024-04-01
    FY 2022
    Sources
    • 10-K · 2023-03-27
    FY 2021
    Sources
    • 10-K · 2023-03-27
    FY 2020
    Sources
    • 10-K · 2021-03-29
    Market Cap$220.5Kcurrent------$2.6Mest.$76.0Mest.$4.6Best.$16.7Best.$16.9Best.
    Revenue$58.9M$13.8M↓8%$15.7M↓5%$13.6M↓22%$64.8M↓15%$76.4M↓23%$99.5M↓6%$105.6M↑35%$78.0M
    Operating Income-$34.7M-$9.5M↓33%-$9.0M↓62%-$9.5M↓23%-$27.2M↑4%-$28.3M↑19%-$34.9M↓136%-$14.8M↑78%-$67.9M
    Net Income-$54.7M-$22.6M↓143%-$11.7M↑41%-$12.4M↓26%-$47.0M↓26%-$37.3M↑15%-$43.7M↓90%-$23.0M↑72%-$81.7M
    EPS (Diluted)--$-12.14↓848%$-8.03↓163%$-17.44↓938%$-71.21↓941%$-6.84↓936%$-0.66↓57%$-0.42↑82%$-2.33
    Gross Margin64.4%64.0%↓3%60.1%↓16%64.2%↓4%68.3%68.3%↑3%66.3%↓5%70.2%↑6%65.9%
    Operating Margin-59.0%-68.9%↓45%-57.6%↓71%-69.8%↓57%-41.9%↓13%-37.1%↓6%-35.1%↓151%-14.0%↑84%-87.0%
    ROE-2045.1%———-1983.8%↓847%265.7%↑149%-540.0%↓861%-56.2%↑70%-184.7%
    Total Debt$30.1M$30.1M↓13%$34.3M↓23%$35.5M↓54%$39.7M↓44%$70.8M↓9%$77.7M↑1%$77.3M↑2%$75.5M
    Shareholders' Equity$2.7M$2.7M↓74%$2.3M↓37%$2.3M↑110%$2.4M↑117%-$14.0M↓273%$8.1M↓80%$40.9M↓7%$44.2M
    Current Ratio0.900.90↓51%1.10↓45%1.28↓38%1.60↓25%2.13↑1%2.12↓33%3.18↓10%3.55
    Debt / Equity11.2511.25↑230%14.73↑22%15.68↑560%16.76↑432%-5.05↓153%9.61↑409%1.89↑11%1.71
    Operating Cash Flow-$20.5M-$4.9M↓60%-$5.4M↓309%-$6.3M↓119%-$11.1M↑14%-$12.9M↑52%-$27.0M↓36%-$19.8M↑31%-$28.6M
    Free Cash Flow-$20.7M-$4.9M-$5.6M↓314%-$6.3M↓119%-$11.2M↑14%-$13.0M↑53%-$27.3M↓35%-$20.3M↑30%-$28.9M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    VERO vs Peers — Financial Grading

    Revenue$64.8MBottom 25%
    Net Income$47.0MBottom 25%
    ROE-1983.8%Bottom 25%
    D/E16.76Bottom 25%
    Op. Margin-41.9%Bottom 25%
    Curr. Ratio1.60Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11